Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)

NCT07327840 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Lipoprotein Disorder

Interventions

DRUG: Kylo-11 or matched placebo

Sponsor

Kylonova (Xiamen) Biopharma co., LTD.